The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
The activities of rifampin, nitazoxanide, PA-824, and sutezolid were tested against dormant Mycobacterium tuberculosis under conditions mimicking caseous granulomas (hypoxia at pH 7.3) in comparison with those of the combination rifampin-isoniazid-pyrazinamide-ethambutol (R-I-Z-E), which is used for human therapy. Mycobacterial viability was monitored by CFU and regrowth in MGIT 960. As shown by lack of regrowth in MGIT, rifampin-nitazoxanide-containing combinations, but not R-I-Z-E, killed dormant cells in 28 to 35 days. These observations might be important in designing new tuberculosis therapies.
['Iacobino|Angelo|A|0000-0002-0176-3662', 'Giannoni|Federico|F|', 'Pardini|Manuela|M|', 'Piccaro|Giovanni|G|', 'Fattorini|Lanfranco|L|']
D000995:Antitubercular Agents D004338:Drug Combinations D004359:Drug Therapy, Combination D004977:Ethambutol D006801:Humans D006863:Hydrogen-Ion Concentration D000860:Hypoxia D007538:Isoniazid D008826:Microbial Sensitivity Tests D009169:Mycobacterium tuberculosis D009593:Nitroimidazoles D023303:Oxazolidinones D011718:Pyrazinamide D012293:Rifampin D014376:Tuberculosis
Mycobacterium tuberculosis tuberculosis hypoxia rifampin nitazoxanide pH